Skip to Main Content

The leaders of the world’s wealthiest nations and several drug makers took steps to widen equitable access to Covid-19 vaccines, such as issuing voluntary licenses to expand manufacturing, increasing donations to a global distribution program, and investing in production capacity in Africa.

Specifically, the G20 leaders asked the World Health Organization and World Trade Organization to compile a report by October on obstacles to greater vaccine access. They also agreed to extend through 2022 a WHO program called Access to Covid-19 Tools Accelerator, or ACT Accelerator, which was created to develop, produce and distribute vaccines, diagnostics and therapies.


Meanwhile, several vaccine makers – Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA) and Johnson & Johnson (JNJ) – pledged to provide 1.3 billion vaccines doses this year to low-income countries at cost and to middle-income countries at “low cost.” Another 1 billion doses were committed for next year and many of the doses will be provided to COVAX, which is part of the ACT Accelerator.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!